Top News

Facet Biotech Acquired By Abbott

Redwood City-based Facet Biotech, a developer of treatments for multiple sclerosis, has been acquired by Abbott, in a deal worth $450M. According to Abbott, it will pay $27 per share in cash for Facet, for a purchase price of approximately $722M less Facet's cash and marketable securities worth $272M. Facet has a drug targeted at treating multiple sclerosis in Phase II traisl, and a number of other oncology compounds in early and mid stage development. Facet Biotech was advised by Centerview Partners in the deal.


 

Marketplace


blog comments powered by Disqus
 

Latest Headlines

Browse Issues